Skip to content

Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes

Physiological Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03056872
Enrollment
60
Registered
2017-02-17
Start date
2018-10-05
Completion date
2023-05-12
Last updated
2023-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder, Anxiety Disorder/Anxiety State, Drinking to Cope, Hypothalamic Pituitary Adrenal, Stress Disorder

Brief summary

Alcohol dependence is among the most common and costly public health problems affecting the nation. Among individuals with alcohol use disorder (AUD), those with (vs. without) a co-occurring anxiety disorder (AnxD) are as much as twice as likely to relapse in the months following AUD treatment. Dysregulation of biological stress-mood systems predict and correlate with AUD relapse and AnxD symptomatology. In contrast, stress system re-regulation correlates with improved AUD treatment outcomes but has not been examined with respect to AUD recovery and relapse in co-occurring AUD+AnxD.

Detailed description

The objectives of the proposed research are to 1) evaluate the effect of co-occurring AnxD on the severity of biological stress-mood system dysregulations in AUD inpatients at pre-treatment, 2) evaluate the effect of co-occurring AnxD on the persistence of stress-mood system dysregulations in AUD inpatients in the months following treatment, 3) evaluate the effects of treatment on biological stress-mood system re-regulation among AUD patients with co-occurring AnxD, and 4) evaluate the effect of re-regulation change in biological stress-mood system function on AUD clinical outcomes.

Interventions

None listed

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of Minnesota
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Ability to provide informed consent * Between the ages of 18 and 65 * Diagnostic and Statistical Manual diagnosis of a Panic Disorder, Generalized Anxiety Disorder, or Social Anxiety Disorder within the past 30 days (AUD+AnxD group only). * Primary alcohol use disorder diagnosis and alcohol use in the 30 days preceding the study (AUD alone and AUD+AnxD groups only). * Inpatient treatment at Lodging Plus primarily for alcohol (vs. other drug with nicotine accepted) dependence (AUD alone and AUD+AnxD groups only). * A minimum of a sixth-grade reading level. * Healthy controls, same criteria absent AUD and AnxD diagnosis of an alcohol and/or anxiety disorder * Lives within proximity to the Twin Cities (e.g., within about an hour's drive) or willing to drive to Fairview for the purpose of attending follow-up visits * Willingness to provide contact information to confirm follow-up appointments

Exclusion criteria

* Lifetime history of psychosis or mania * Cognitive impairment, physical impairment, or chronic medical illness that precludes study participation * Primary PTSD as determined by qualifying assessment * Females currently pregnant * Exposure to antipsychotic medication for a total duration \>16 weeks. * Prior head injury leading to \>30 minutes of unconsciousness. * Cognitive impairment that impedes study participation. * Healthy controls with a history of any major medical or psychiatric disorders (e.g., schizophrenia, depression, heart disease, or stroke). * Suicide intent or attempt in the past 30 days * Cardiovascular health issues * Thyroid Disease * History of severe neurological illness such as chronic seizure disorder (e.g, epilepsy) or stroke * Brain tumor and/or implants in the skull cavity (e.g., plate in the skull) * Pacemaker

Design outcomes

Primary

MeasureTime frameDescription
Relapse Status4-month follow-upRelapse status will be assessed using a categorical measure of whether someone did vs did not drink (yes vs. no) during the 4 months following treatment discharge.
Relapse Severity4-month follow-upRelapse severity will consist of the number days drinking during the 4 months following treatment discharge.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026